Oral small molecules in ulcerative colitis — the JAK inhibitors, S1P receptor modulators, and emerging therapies (tofacitinib, upadacitinib, ozanimod, etrasimod) offering pill-based alternatives to injectable biologics representing the fastest-growing formulation segment — create the most patient-preferred market opportunity, with the Ulcerative Colitis Market reflecting oral...